Abstract
Autologous fat grafting to the breast has become prevalent worldwide for reconstructive and aesthetic purposes because of its low rate of complications and the versatility and convenience of a nonimmunogenic filler. [1] [2] [3] [4] [5] [6] [7] [8] [9] Lipofilling has broad applicability for complex breast reconstruction, including the treatment of radiation sequelae. 1, 3, 10, 11 However, fat grafting has not been recommended by the American Society of Plastic Surgeons because it poses a theoretical oncologic risk that is particularly concerning for women with a genetic predisposition to breast cancer, precancerous lesions, or active breast cancer. [12] [13] [14] [15] [16] This risk originated from the association of obesity and breast cancer in humans and from results of in vitro and preclinical laboratory studies that identified cells in human adipose tissue (eg, adipocytes and adipose-derived stem/stromal cells [ADSCs] ) that exhibit cancer-promoting activities in the breast microenvironment. 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] However, investigators have shown repeatedly that autologous breast lipofilling is not a risk factor for breast cancer in clinical practice. 1, 3, 10, 26, 27 The results of laboratory analyses have indicated 3 characteristics of white adipose tissue (WAT) that contribute to cancer risk: (1) chronic inflammation induced by adipokines that results in macrophage recruitment, (2) cell proliferation induced by perivascular macrophages and ADSCs, and (3) elevated concentration of plasminogen activator inhibitor (PAI)-1 in adipocytes. PAI-1 has been found to decrease apoptotic activity and promote degradation of the extracellular matrix, thereby facilitating development, growth, and invasion of tumors. 20, 23, [28] [29] [30] [31] [32] [33] WAT has known oncologic risk for many types of cancer, especially under specific conditions, such as obesity. 25 However, the transplantation of autologous WAT to the breast, an environment naturally comprising fat tissue, may not pose this risk. Prospective clinical studies to validate the risk of WAT transplantation in breast lipofilling have not been performed, presumably because the collection of lipofilled breast tissues for analysis is complex, and the recruitment of matched control patients may not be feasible. In a comparative rat model, native unmanipulated WAT yielded a precancerous breast microenvironment when animals consumed a high-energy diet; fat grafting under normal diet conditions did not induce a precancerous state. 34 In this study, we analyzed rat mammary tissues grafted with healthy autologous WAT. This rat model reproduces lipofilling of the human breast with high fidelity. 1, 39 
METHODS

Animals and Study Design
Nine female Sprague-Dawley rats from the same litter were evaluated as an animal model of cancer following breast lipofilling. This breed was selected because it has welldefined susceptibility to breast cancer development upon exposure to a risk factor at 8 weeks of age. 35, 36 When the experiments were conducted, the animals were 8 weeks old and virgin for pregnancy, and were comparable to a human teenager in terms of breast development. This study was conducted in accordance with the ARRIVE guidelines, set forth by Kilkenny et al, 37 and with the Ethical Principles for Animal Research, established by the Brazilian College for Animal Experimentation. This study was approved by The Committee for Ethics in Animal Research at the University of Campinas (São Paulo, Brazil).
Animals underwent fat grafting in September 2013 and were euthanized for tissue collection and analysis in November 2013. During the period after fat grafting until the obtainment of mammary samples for analysis, rats were housed in isolated boxes that were cleaned daily and were maintained under controlled illumination (12 hours/ day) and constant temperature (20 to 22°C).
Three pairs of thoracic mammary glands per animal (54 total breasts) were included in the analysis. For each group, 3 rats received autologous fat harvested subcutaneously, 3 rats received autologous fat harvested from the great omentum, and 3 rats were not manipulated (negative control).
Fat Harvesting and Preparation of WAT
Eight-week-old rats received general anesthesia, delivered intraperitoneally. Omental fat was harvested by laparotomy (midline incision of ~4 cm long). Subcutaneous fat was obtained through skin incisions (~2 cm long) made over the left and right iliac fossae. The abdominal wall and skin incisions were closed with 5-0 nylon running sutures.
Fat tissue was manually cut with a scalpel into very small pieces and was placed into a 10-mL syringe. The fat was expelled through this syringe into another 10-mL syringe through an emulsifier (Tulip Medical Products, San Diego, CA) to yield homogeneously fragmented donor fat. The fat was then centrifuged at 3000 rpm for 3 minutes, and the middle layer, containing viable adipocytes, was transferred to a 1-mL syringe.
A 0.2-mL aliquot of prepared autologous fat was grafted into the thoracic mammary gland through a 0.9-mm blunttip cannula, as described previously. 1, [38] [39] [40] The rats were euthanized 8 weeks postoperatively (ie, 112 days old), and breast tissues were harvested for analysis. This 8-week duration was based on previous studies in which a rat model of breast cancer was established. 35, 41 
Histologic and Immunohistochemical Analyses
Tissue samples were fixed in 10% buffered formalin and embedded in paraffin by standard methods at the Laboratory of Specialized Pathology, State University of Campinas. Tissues were sectioned at 4 μm and were stained with hematoxylin and eosin or analyzed by immunohistochemistry. Prior to antibody exposure, heat-induced antigen retrieval was conducted with either tris-EDTA buffer (pH 9.0) or citrate buffer (pH 6.0; utilized prior to anti-Ki67 exposure only). Tissue sections were incubated with the following primary antibodies: anti-CD68 (clone KP-1, 1:1000; Cell Marque, Rocklin, CA), anti-PAI-1 (1:100; Abcam, Cambridge, MA), anti-Ki67 (1:50; Millipore Darmstadt, Germany), and anti-estrogen receptor (ER; clone 1D5, 1:300; Dako, Glostrup, Denmark). Antigen-antibody interactions were detected by means of a biotin-free polymer (Advance, Dako). Immunostaining was visualized with diaminobenzidine, and counterstaining was performed with hematoxylin. Positive and negative controls were included for each batch. For detection of CD68 and PAI-1, brownish staining of the cytoplasm was considered a positive result. For detection of Ki67 and ER, brownish nuclear staining was regarded as a positive result.
The number of terminal duct lobular units of the breast and the number of epithelial cell layers in the lobular ducts were determined by examining a hotspot field on each slide under magnification (×400). These fields also were evaluated for morphology of ductal cells (ie, flat epithelium, cuboidal epithelium, modifications to columnar cells) and for the presence of ductal ectasia, papillary lesions or projections, and nuclear atypia. A pathologist (L.R.M.), blinded to the origin of each sample, performed immunohistochemical analyses and identified cell morphologies in ten high-power fields (HPF, ×400 magnification) in a histology section. For Ki67, ER, and PAI-1, the percentages of marker-positive cells were determined. For CD68, the numbers of marker-positive cells outside the vascular lumen were counted. 42, 43 The distribution of PAI-1 in the mammary gland and patterns of PAI-1 among the 3 groups also were evaluated. 44, 45 Ki67-positive cells and ER-positive cells were counted in each terminal lobular duct, and values were compared for each sample. The ratio of ER-positive cells to Ki67-positive cells was determined for each breast, and these ratios were compared among the 3 groups. Precancerous status can be inferred by an abundance of these cells in the lobular ducts. 31, 46, 47 
Real-Time PCR
An RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) was employed for extraction of total RNA. Ki67 mRNA and PAI-1 mRNA were quantified by means of real-time reverse transcription (RT) polymerase chain reaction (PCR) with an ABI Prism 7500 (Applied Biosystems, Foster City, CA). Total RNA was reverse-transcribed to cDNA with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). PCR was achieved with primers recognizing Ki67 (Rn.PT.58.8428180.g; Integrated DNA Technologies, Coralville, IA), PAI-1 (Rn01481341_m1; Applied Biosystems), and GAPDH (4352339E; Applied Biosystems; included as a reference gene). The reaction mixture for PCR included 40 ng of cDNA, 0.25 μL of each primer, 3 μL of TaqMan Universal Master Mix (Applied Biosystems), and RNase-free water to a final volume of 10 μL. Data were analyzed with an ABI 7500 Sequence Detection System (Applied Biosystems).
Statistical Analyses
All statistical analyses were carried out with SPSS (MacOS, version 20; IBM, Armonk, NY). Normality of the distribution was determined with Kolmogorov-Smirnov and Shapiro-Wilk tests. Significant differences among normally distributed data were ascertained with paired t tests, analysis of variance (one-way and repeated measures), and Tukey's test (post hoc), and values were expressed as mean ± standard deviation (SD). Data with non-normal distribution were analyzed with the Kruskal-Wallis test, and values were expressed as medians and quartiles. Statistical significance was defined as P < 0.05.
RESULTS
Epithelial hyperplasia was not observed in ductal structures. The 3 groups did not differ significantly in the quantity of intraductal epithelial layers (overall mean, 1.56 ± 0.58 layers; overall range, 1-3 layers, P = 0.15). No cystic alterations, papillary lesions or projections, or nuclear atypia were observed. The numbers of terminal duct lobular units were similar for the 3 groups; the overall mean was 8.20 ± 2.26 (P = 0.62) ( Table 1 and Figure 1) .
The immunohistochemical findings for CD68, a marker of macrophages, did not differ significantly for lipofilled and unmanipulated rat mammary tissue. For the 3 groups, an average of 5.6 ± 1.4 macrophages per 10 micrographic fields was observed, and the macrophage concentration did not differ among the groups (P = 0.53; Tukey's posthoc test; P = 0.24) ( Table 1 and Figure 2A ).
Ki67-positive cells constituted an average of 2.54% of all cells, and the percentages of Ki67-positive cells were similar for the 3 groups (median, 2%; quartile [Q]1, 1%; Q3, 3%; P = 0.34; Figure 2B ). The mean concentration of ER-positive cells was 27.92% (range, 23.26%-32.57%), and breasts grafted with subcutaneous or omental fat were similar to controls in regard to this metric (P = 0.22) ( Table 1 and Figure 2C ). The ratios of estrogen receptor (ER)-positive cells to Ki67-positive cells were similar for the 3 groups (control, 20.20 ± 14.68; grafted with subcutaneous fat, 12.50 ± 5.69; grafted with omental fat, 11.50 ± 9.20; P = 0.26) ( Table 1 and Figure 2D ).
Representative immunohistochemical findings are shown in Figure 3 . Regardless of treatment group, we observed moderate PAI-1 reactivity that was distributed among ductal cells, adipocytes, fibroblasts, and macrophages. The patterns of PAI-1 reactivity were similar for all groups (Table 2 and Figure 4) .
Expression of Ki67 mRNA did not differ significantly among the treatment groups (P = 0.71) ( Table 1 and Figure 5A ). PAI-1 mRNA levels were similar for lipofilled and control breasts (P = 0.94). Similarly, mRNA levels of urokinase plasminogen activator (uPA), of which PAI-1 is a major inhibitor, were similar for the 3 groups (P = 0.75) ( Table 1 and Figures 5B-C).
DISCUSSION
The Sprague-Dawley rat is a well-established animal model of mammary gland development and of carcinogenesis susceptibility of the breast. 35, 36, 41, 48 Several investigators have determined that an 8-week period after fat grafting to rat breasts is sufficient to evaluate precancerous status and represents chronic exposure (~10 years in humans) to transplanted adipose tissue. 34, 36, 48 Examining breast tissue more than 8 weeks after fat grafting could introduce bias related to the age of the rat; this breed is prone to the development of breast cancer even after exposure to weak inductors. 36 We performed fat grafting with adipose tissue obtained subcutaneously and from the omentum. Transfer of omental fat was included to evaluate whether the breast microenvironment was influenced by WAT lineage.
With this animal model, we demonstrated that transplantation of healthy adipose tissue to the breast did not induce a precancerous status. The cell staining patterns for Ki67, ER, and PAI-1 in the breast did not change 8 weeks after fat grafting. Moreover, mRNA expression levels of Ki67 and PAI-1 were similar for lipofilled and control breasts. Our histologic findings indicate that autologous grafting of WAT does not change the morphology of mammary ducts or yield nuclear atypia or cell proliferation. When transplanted to the breast, autologous WAT appears to incorporate into existing adipose tissue without affecting the paracrine activity of native cells. 34 Macrophages infiltrate tissues in response to inflammation. These cells populate adipose tissue of patients with plurimetabolic syndrome and/or insulin resistance. 49 Macrophages also exist in cancerous breast tissue; macrophage infiltration of the breast is associated with accelerated disease invasion and progression. 29, 33, [50] [51] [52] [53] [54] [55] In the current study, macrophages were identified by a pathologist on the basis of cell morphology and as CD68-positive cells. Grafted fat has been shown to recruit CD68-expressing macrophages, which might lead to tumor induction. 29, 33, [50] [51] [52] 54, 55 Because the pattern of CD68 reactivity in lipofilled rat mammary tissues was similar to that of control breasts, our results suggest that fat grafting to the breast does not trigger macrophage infiltration.
Ki67 is a cellular marker of proliferation and differentiation. [56] [57] [58] [59] [60] [61] [62] [63] In the present study, Ki67 was examined in ductal cells by immunohistochemical methods. In addition, the mRNA expression of Ki67 was determined as a measure of the proliferation rate in whole mammary tissue, including adipocytes and ADSCs from the transplanted fat. Grafted fat is thought to induce proliferation at the recipient site because adipose tissue promotes angiogenesis immediately after grafting. [64] [65] [66] [67] [68] Theoretically, this phenomenon would increase breast cancer risk. However, we found that fat grafting to the breast apparently does not increase cell proliferation at the recipient site. An increased quantity of fat tissue in the breast (eg, from lipofilling) has been hypothesized to increase the proportion of ER-positive luminal epithelial cells. In normal breasts, a high density of ER-positive cells results in decreased Ki67 expression. Women who are younger would be expected to have lower ER levels and higher Ki67 levels than women who are older and have more breast fat. When the balance between ER-positive cells and cell proliferation is disrupted (ie, high ER and high Ki67), the microenvironment becomes precancerous. 31, 46, 47 We demonstrated that fat grafting to the rat breast neither increases ER positivity in ductal cells nor disrupts the balance between ER expression and cell proliferation in breast lobules.
Although PAI-1 is secreted by various cells, it is expressed primarily in adipocytes, which release PAI-1 at dangerous levels in conditions such as obesity, hyperinsulinemia, hyperglycemia, and hypertriglyceridemia. 21, 69 PAI-1 functions in tissue repair processes and is involved in decreasing apoptotic activity and degrading the extracellular matrix during tumor growth, invasion, and metastasis. [69] [70] [71] [72] [73] Therefore, PAI-1 is a predictor of breast cancer risk and unfavorable breast cancer progression. 21, 28, 32, 44, 53, [70] [71] [72] 75 Fat grafting is thought to increase the concentration of PAI-1 at the recipient site. However, we found that lipofilled breasts and unmanipulated breasts exhibited moderate PAI-1 reactivity and similar PAI-1 localization to ductal cells, fibroblasts, adipocytes, and macrophages. Moreover, no changes in mRNA expression or immunogenic reactivity of breast lobules were detected among the treatment groups. The breast is naturally rich in fat. Even after mastectomy, surrounding tissues (including any residual cancerous cells) remain in proximity with fat cells and continue to be exposed to the paracrine activity of native fat cells. 19, 23, 34, [76] [77] [78] The oncogenic risk associated with fat transfer may apply only to body compartments lacking an abundance of native fat cells. We demonstrated previously that fat grafting was not sufficient to induce an oncogenic status in rat mammary tissue. However, rats exposed to a high-energy diet exhibited tissue proliferation and increased PAI-1, even in the absence of fat grafting. 34 Mature adipocytes are regarded as more carcinogenic than immature adipocytes or ADSCs because adipokines released from mature adipocytes are more likely to promote inflammation and trigger a cascade of events involving macrophage recruitment, epithelial-to-mesenchymal transition, cell proliferation, and differentiation. 24, 77 Moreover, transplantation of mature adipocytes is postulated to increase the concentration of PAI-1 in the breast microenvironment. We suggest that adipocytes transplanted to the breast do not increase adipokine levels because adipocytes native to the recipient site possess their own paracrine activity. 19, 34 This study was limited because we analyzed an animal model of breast cancer rather than patients who underwent lipofilling with or without concomitant breast cancer. Moreover, we did not deliver a chemical carcinogen to induce breast cancer in our animal model. Instead, fat was transferred to healthy rat mammary tissue, which may be perceived as a limitation. However, delivering autologous fat in a background of breast cancer could introduce false-positive bias. In the context of existing breast cancer, it would not be possible to perform a cell-signaling study to detect mediators of inflammation, proliferation, or differentiation because these signaling components could have been influenced by the exogenous carcinogen. Moreover, any molecular changes detected in lipofilled tissues could not be attributed to lipofilling alone, because all cells in the animal (including native breast cells, grafted adipocytes, and ADSCs) could have been affected by exposure to the carcinogen. These cells, in turn, could yield unpredictable effects in the breast microenvironment.
Adipocytes are specialized for storing energy by means of cytoplasmic lipid droplets. If we had exposed rats to a cancer inductor prior to fat grafting, native adipocytes of the rat mammary tissue likely would have stored the inductor (eg, DMBA, 7,12-dimethylbenzanthracene, and MNU, N-methyl-N-nitrosourea, are lipophilic agents), thereby increasing its concentration in the breast microenvironment and potentially introducing false-positive bias in the lipofilled groups.
To our knowledge, this study is the first to address cancer risk of the lipofilled breast in an animal model. Investigators have identified the tumorigenic potential of adipose tissue; however, the results of studies conducted in the past 30 years have not supported an increased oncogenic risk among patients who undergo breast lipofilling, including those with a history of breast cancer. 1, 3, 12, 26, 27, [79] [80] [81] We believe that these preclinical results were not realized in clinical practice because lipofilling was not previously analyzed in vivo. Our results are consistent with clinical observations; we found that molecular markers of precancerous status were not elevated in a controlled animal model of fat grafting to the breast.
For patients who undergo breast lipofilling after treatment for breast cancer, an increase in the local concentration of stem cells is a concern because these progenitors may increase cell proliferation and differentiation in the breast. However, stem cells primarily are recruited from surrounding native WAT and blood circulation by the release of growth factors and cytokines from a tumor. 23, 78, 82 The concentration of stem cells transferred to the breast with lipofilling does not appear to be sufficient for cancer induction.
Based on results of the current study and our previous findings, 34 we suggest that breast lipofilling does not pose an increased risk of local tumorigenesis, even for patients with a history of breast cancer. Additional experimental studies are warranted to validate our results regarding the cellular and molecular behaviors of autologous fat grafted to the breast.
CONCLUSIONS
In this in vivo study, we demonstrated that breast lipofilling with healthy autologous tissue had no effect on the morphology of the mammary ducts, the proliferative rate of mammary lobules, the balance of cells expressing ER or Ki67, macrophage-mediated inflammation, PAI-1 levels, or PAI-1 distribution in breast lobules. Findings from other preclinical studies have indicated an oncogenic risk of WAT, especially in the presence of cancer cells or other oncogenic risk factors. However, this theoretical risk has not been supported by clinical observations. The breast should be regarded as uniquely robust to the tumorigenic potential of transplanted WAT. Fat tissue native to the breast exhibits endogenous paracrine activity, and lipofilling alone is insufficient to induce a precancerous status in the breast.
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